
HSCS Stock Forecast & Price Target
HSCS Analyst Ratings
Bulls say
HeartSciences is poised for growth with its suite of AI-ECG diagnostic solutions and cloud-based platform, MyoVista Insights. Despite the need for additional financing, the company has multiple facilities in place to address this issue. The recent FDA submission for the MyoVista wavECG device is a significant milestone and the company's careful spending has resulted in a lower cash burn rate and improved earnings estimates. Risks include dilution, execution challenges, and regulatory hurdles, but with a NPV analysis pointing to 3x upside potential and favorable risk/reward, HeartSciences presents an attractive opportunity for investors.
Bears say
HeartSciences is striving towards a promising and valuable use of AI in the medical field, with its MyoVista device and cloud software platform being approved and positioned to capture a large portion of the US annual ECG tests. With a current focus on early detection and prevention, and a potential to save lives and reduce healthcare costs, the company's revenues are expected to be significant and could result in long-term success. Additionally, operating expenses remain at a manageable level and a recent equity financing has increased the number of shares, indicating a healthy growth trajectory.
This aggregate rating is based on analysts' research of Heart Test Laboratories Inc and is not a guaranteed prediction by Public.com or investment advice.
HSCS Analyst Forecast & Price Prediction
Start investing in HSCS
Order type
Buy in
Order amount
Est. shares
0 shares